A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Conditions: Multiple Myeloma; Non-Hodgkin Lymphoma; B-Cell Lymphoma Interventions: Drug: Tiragolumab; Drug: Daratumumab; Drug: Rituximab Sponsor: Genentech, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials